<DOC>
	<DOC>NCT00799552</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.</brief_summary>
	<brief_title>Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Signs and Symptoms</mesh_term>
	<criteria>Be at least 18 years of age; Have provided written informed consent; Have a history of dry eye for at least 6 months prior to enrollment; Have a history of use or desire to use eye drops for dry eye symptoms within the past 6 months; Demonstrate a response when exposed to the CAE. Have an ongoing ocular infection, or active ocular inflammation Have worn contact lenses within 72 hours of Visit 1 or have anticipated use of contact lenses during the study; Have contact lensinduced dry eye; Have previously had laser in situ keratomileusis (LASIK) surgery; Be using or have anticipated use of temporary punctual plugs during the study; Have best corrected visual acuity &gt; +0.7 in both eyes; Be a woman who is pregnant, nursing or planning a pregnancy; Have a known allergy and/or sensitivity to the test article or its components; Be currently using any medication known to cause ocular drying that is not used on a stable dosing regimen for at least 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Keratoconjunctivitis Sicca</keyword>
	<keyword>Dry eye</keyword>
	<keyword>Resolvin</keyword>
</DOC>